Azenta (NASDAQ:AZTA – Get Free Report) and Mitesco (OTCMKTS:MITI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.
Valuation and Earnings
This table compares Azenta and Mitesco”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Azenta | $593.82 million | 2.30 | -$55.76 million | ($1.35) | -21.98 |
| Mitesco | $40,000.00 | 38.97 | -$2.51 million | ($0.14) | -0.64 |
Risk & Volatility
Azenta has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Mitesco has a beta of 5.56, indicating that its share price is 456% more volatile than the S&P 500.
Profitability
This table compares Azenta and Mitesco’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Azenta | -10.34% | 1.43% | 1.19% |
| Mitesco | -7,638.20% | N/A | -2,270.77% |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Azenta and Mitesco, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Azenta | 1 | 3 | 4 | 0 | 2.38 |
| Mitesco | 0 | 0 | 0 | 0 | 0.00 |
Azenta presently has a consensus target price of $41.33, suggesting a potential upside of 39.31%. Given Azenta’s stronger consensus rating and higher probable upside, research analysts clearly believe Azenta is more favorable than Mitesco.
Institutional and Insider Ownership
99.1% of Azenta shares are held by institutional investors. Comparatively, 0.0% of Mitesco shares are held by institutional investors. 10.9% of Azenta shares are held by insiders. Comparatively, 4.9% of Mitesco shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Azenta beats Mitesco on 9 of the 14 factors compared between the two stocks.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
About Mitesco
Mitesco, Inc. does not have significant operations. Previously, it was engaged in healthcare technology and services business. Mitesco, Inc. is based in Vero Beach, Florida.
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
